Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also commented on HRTX. Jefferies Group LLC reaffirmed a buy rating on shares of Heron Therapeutics in a research report on Wednesday, August 16th. Northland Securities initiated coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They set an outperform rating and a $40.00 price target for the company. Noble Financial reaffirmed a buy rating and set a $24.00 price target on shares of Heron Therapeutics in a research report on Friday, October 6th. Zacks Investment Research raised Heron Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a research report on Wednesday, July 12th. Finally, BidaskClub lowered Heron Therapeutics from a hold rating to a sell rating in a research report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of Buy and an average target price of $28.50.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up 1.821% during midday trading on Thursday, reaching $15.375. The company’s stock had a trading volume of 475,300 shares. The company’s 50-day moving average price is $15.64 and its 200 day moving average price is $15.24. The company’s market capitalization is $832.37 million. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. On average, equities research analysts forecast that Heron Therapeutics will post ($3.50) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Analysts Give Heron Therapeutics, Inc. (HRTX) a $31.00 Price Target” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://theolympiareport.com/2017/10/30/cantor-fitzgerald-analysts-give-heron-therapeutics-inc-hrtx-a-31-00-price-target.html.

Several large investors have recently made changes to their positions in HRTX. Janus Henderson Group PLC bought a new position in shares of Heron Therapeutics in the 2nd quarter worth approximately $78,134,000. Vanguard Group Inc. raised its position in shares of Heron Therapeutics by 40.2% in the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after acquiring an additional 537,563 shares in the last quarter. State Street Corp raised its position in shares of Heron Therapeutics by 30.7% in the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after acquiring an additional 420,113 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Heron Therapeutics in the 1st quarter worth approximately $2,002,000. Finally, Credit Suisse AG raised its position in shares of Heron Therapeutics by 329.8% in the 1st quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock worth $2,161,000 after acquiring an additional 110,539 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.